MGB Biopharma’s focus is to further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.

The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000.

There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective.

The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, is currently in Phase I clinical safety studies, which will reach completion at the end of 2015. MGB-BP-3 is just the first in our new exciting class of anti-infectives.

MGB Biopharma commenced operations in 2010, and is funded by a syndicate of some of Scotland’s leading business angels, in co-operation with Scottish Enterprise.

Innovate UK

Archangels

Barwell Plc

Scottish Investment Bank

TRICAPITAL

Highlands and Islands Enterprise

SyndicateRoom

MGB Biopharma Limited

Immuron is a pharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases.

Immuron

Rebiotix is a biotechnology company specializing in the development of microbiota-based therapies for various diseases, including clostridium difficile infection.

Rebiotix

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on the development of anti-infectives for multi-drug resistant pathogens.

Iterum Therapeutics plc

Cidara Therapeutics Inc is a biotechnology company developing novel anti-infectives for the treatment of serious fungal and bacterial infections.

Cidara Therapeutics Inc

Venatorx Pharmaceuticals Inc is a pharmaceutical company focused on the discovery and development of novel anti-infective agents.

Venatorx Pharmaceuticals Inc

MGB Biopharma is dedicated to developing a new class of anti-infective medicines, particularly antibiotics based on Minor Groove Binder (MGBs) compounds. Their lead drug candidate, MGB-BP-3, has shown promising results in a Phase IIa clinical proof of concept study for the treatment of Clostridium difficile-associated diarrhea (CDAD).

MGB Biopharma

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 7, 2024 10:34 PM	440ff362
news impact assignment basic	general	Mar 7, 2024 10:34 PM	86abc31c
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 10:34 PM	ca4c21b0
company summary	general
signals	general	Mar 7, 2024 10:34 PM	e340bd30
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Mar 7, 2024 10:34 PM	080b0d19
news basic	general	Mar 7, 2024 10:34 PM	db984470
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
purchaser profile	merger_acquisitions
customer profile	customers

COM:MGB-BIOPHARMA

MGB Biopharma